Vilon.
Vilon is a synthetic dipeptide, L-lysyl-L-glutamate (Lys-Glu), one of the short peptide bioregulators developed by Vladimir Khavinson's St.
Vilon is a synthetic dipeptide, L-lysyl-L-glutamate (Lys-Glu), one of the short peptide bioregulators developed by Vladimir Khavinson's St. Vilon is research / preclinical, and PepCue grades its published evidence F tier (15/100). Also known as Lys-Glu dipeptide. This is a research reference, not medical or dosing advice.
What it is
Vilon is a synthetic dipeptide, L-lysyl-L-glutamate (Lys-Glu), one of the short peptide bioregulators developed by Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology in Russia. It was designed as a minimal synthetic analogue reflecting active sequences found in thymic peptide preparations such as thymalin. Despite its very small size, it is promoted as a geroprotective and immunomodulatory agent. It is a research compound with no approved medical use.
How it works
Vilon is hypothesized to act as a gene-regulating bioregulator: proponents propose that the dipeptide can penetrate cells, bind DNA and histones, and alter chromatin accessibility to switch on genes silenced with aging. In immune tissue it is reported to activate T-helper cells and modulate age-associated immune changes. Some microarray studies from the originating group describe changes in gene expression in mouse tissues after vilon exposure. As with other Khavinson peptides, these mechanistic claims rest mainly on the developing laboratory's own experiments rather than on independent confirmation.
Mechanism pathways
Short peptides hypothesized to enter cells and influence tissue-specific gene expression.
This group is defined by a shared hypothesis rather than a shared receptor, and the hypothesis is what makes it unusual. The peptide bioregulator concept originated in a single research programme in Russia beginning in the 1970s, initially with peptide extracts prepared from animal organs and later with very short synthetic peptides, typically two to four amino acids, said to reproduce the extracts' activity. The proposal is that these peptides are small enough to cross both the cell membrane and the nuclear envelope without a dedicated transporter, bind directly to DNA promoter regions or to histones, alter chromatin accessibility, and thereby switch on genes that have become silenced with age. Each peptide is claimed to be tissue-specific, acting on the organ its parent extract came from, so a thymus-derived preparation is proposed to act on immune tissue, a pineal-derived one on the pineal gland, and so on. Supporting observations cited by the originating group include reports that some of these peptides bind oligonucleotides in biophysical assays, that fluorescently labelled versions enter the nuclei of cultured cells, and that microarray studies show altered gene expression in treated animal tissues. Reported downstream effects vary by peptide and include changes in immune cell populations, antioxidant enzyme expression, apoptosis markers, and neurotransmitter-related gene expression. The honest assessment must be direct, because this pathway is unusually vulnerable to overstatement. Almost all of the mechanistic and outcome evidence originates from the same laboratory and its close collaborators, published substantially in Russian-language or low-circulation journals, and it has not been independently replicated by unaffiliated groups. Sequence-specific DNA binding by a two-, three-, or four-residue peptide is chemically difficult to reconcile with what is known about how transcription factors achieve specificity, since recognition of a unique genomic site generally requires a much larger binding surface. Longevity and health claims attached to these compounds frequently rest on studies that were not blinded, not randomised, or not controlled, and that were conducted by the same group that developed the products. None of these compounds is an approved medicine in the United States, the European Union, or the United Kingdom, though some have regulatory status in Russia and neighbouring countries. Material sold internationally is unregulated. The proposed mechanism should be understood as an unconfirmed hypothesis, not an established pathway.
The evidence
The vilon evidence base is almost entirely preclinical and comes from Vladimir Khavinson, Vladimir Anisimov and colleagues, published largely in Russian journals. Reported findings include inhibition of spontaneous and chemically induced tumors and increased lifespan in mice, plus effects on biological-age markers and gene expression. These are animal and cell studies from a single research tradition; there are essentially no independent Western randomized controlled trials or robust human efficacy data. To state it plainly: there are no human clinical trials of vilon in the mainstream indexed literature, so every claim about human benefit is an extrapolation from rodent and cell-culture work. The animal studies are typically conducted in inbred mouse strains at a single institution, with lifespan and tumor incidence as endpoints, without blinded pathology review, without preregistration, and without replication in a second laboratory using a different animal facility and diet, all of which are known to influence rodent lifespan results. The mechanistic work is similar in character: microarray and cell-culture studies attributing changes in gene expression to direct dipeptide interaction with DNA and histones, reported by the originating group and by a small number of collaborating laboratories, including studies of short peptides in stem cell differentiation and in monocyte and macrophage cell lines. The internal consistency of results within the group is notable, but the lack of external replication is a major limitation. Claims of anti-aging or immune benefit in humans should therefore be regarded as unproven. Compared with its siblings in the same Khavinson tradition, vilon sits at the least developed end: thymalin and cortexin at least have registered clinical use and observational human reports in Russia, and Cerebrolysin, an unrelated animal-tissue peptide preparation, has enough independent randomized trials to have been assessed twice by Cochrane. Vilon has none of that. There is no published modern toxicology dossier, no human pharmacokinetic data, and no regulatory dossier available for external review.
The evidence, in brief
A synthetic dipeptide (Lys-Glu) from the same Khavinson bioregulator tradition as thymalin. Reported anti-tumour and lifespan effects come from mouse studies published by a single research group, largely in Russian journals, with no independent Western replication. There is no human efficacy or safety data, and it is sold only as a research chemical.
- Khavinson VKh, Anisimov VN: A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits spontaneous tumours and increases life span of miceDokl Biol Sci, 2000 (PMID 10944717)
- Effect of vilon on biological age and lifespan in miceBull Exp Biol Med, 2000 (PMID 11140587)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #068
Little indexed evidence or largely speculative.
Mostly online reports, no real study base yet.
Claim receipts
Popular claims about Vilon, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Lifespan findings come from mouse studies conducted by the originating group, without replication in an independent laboratory.
Tumor-inhibition results are rodent data from the same single research tradition, with endpoints assessed without blinded review or preregistration.
There are no human clinical trials of vilon in the mainstream indexed literature, so human claims are extrapolation from rodent and cell work.
No human trial means no adverse-event record, and no modern toxicology package has been published for external review.
Safety profile
In the animal studies reported by its developers, vilon appears to be well tolerated at the doses tested, with low toxicity described. However, there is no meaningful independent human safety data, no long-term human studies, and no regulatory safety review outside its originating context. Because no human trial has been conducted, there is no adverse-event table to consult: statements that vilon is safe in people are assertions rather than findings. The absence of a published modern toxicology package is the specific gap that matters, since a regulator would expect repeat-dose toxicity in two species, genotoxicity testing, reproductive toxicity, local tolerance at the injection site, and immunogenicity assessment before any first-in-human study. None of that is available in the indexed literature. The identity and purity of material sold as vilon for research use are not guaranteed, and lyophilized vials distributed through research-chemical channels are not manufactured to pharmaceutical standards, are not tested for sterility or bacterial endotoxin, and may differ from the labeled peptide in content or purity. Injecting a non-sterile preparation carries the ordinary hazards of contamination, including local infection and systemic febrile reactions. A compound proposed to alter gene expression and immune cell behavior also warrants caution in anyone with a history of malignancy or autoimmune disease, a question that has never been addressed experimentally in humans. This is educational information only and not medical or dosing advice.
Compound notes
- Vilon is a synthetic dipeptide, L-lysyl-L-glutamate (Lys-Glu), one of the short peptide bioregulators from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology.
- It was designed as a minimal synthetic analogue of active sequences found in thymic peptide preparations such as thymalin.
- Proponents hypothesize it penetrates cells and binds DNA and histones to alter chromatin accessibility and switch on genes silenced with aging.
- Reported findings, including inhibition of spontaneous and chemically induced tumors and increased lifespan, come from mouse studies by a single research group.
Vilon is the two-amino-acid synthetic distillate; thymalin is the original calf-thymus fraction it was modeled on.
- Not approved as a drug by the FDA, EMA, or other major Western regulators, and not a dietary supplement; it is sold only as a research chemical.
- There is no meaningful independent human safety data and no long-term human studies.
- Identity and purity of material sold for research use are not guaranteed.
Regulatory status
Vilon is not approved as a drug by the US FDA, the European Medicines Agency, or other major Western regulators, and it is not a dietary supplement. It is sold and used only as a research chemical, and human clinical use is not sanctioned in the US.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Synthetic dipeptide L-Lys-L-Glu (lysine plus glutamate)
- 02A Khavinson short peptide bioregulator modeled on thymic peptides
- 03Proposed to act at the DNA/chromatin level to reactivate aging-silenced genes
- 04Main findings (anti-tumor, lifespan) are from mouse studies by one group
- 05No independent Western RCTs or robust human data
- 06Research chemical only; not FDA or EMA approved
Vilon: research formats
Choose the format you are researching to see route-specific notes.
A synthetic dipeptide with no independent human data. Nothing establishes a human route or schedule.
Vilon is the synthetic dipeptide L-lysyl-L-glutamate, designed by the Khavinson group as a minimal analogue of active sequences in thymic peptide preparations. Its main findings, on anti-tumor activity and lifespan, come from mouse studies by one group. There are no independent Western randomized trials or robust human data, so no human administration format exists and this page presents no example amounts.
The proposed mechanism, direct action at the DNA and chromatin level, has not been established in humans and does not imply anything about how the peptide would be delivered to a person.
Vilon is not approved as a drug by the FDA or EMA and is not a dietary supplement. It is sold and used only as a research chemical.
Sources
Every factual claim above resolves to a real, published source.
- A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of miceKhavinson VKh, Anisimov VN. Dokl Biol Sci. 2000 (PMID 10944717)
- Effect of vilon on biological age and lifespan in miceBull Exp Biol Med. 2000 (PMID 11140587)
- PubMed search: vilon Lys-Glu dipeptide bioregulatorLive PubMed query, predominantly single-group animal studies
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell LineAvolio F, Martinotti S, et al. Int J Mol Sci. 2022 (PMID 35408963)
- Effect of short peptides on neuronal differentiation of stem cellsCaputi S, Trubiani O, et al. Int J Immunopathol Pharmacol. 2019 (PMID 30791821)
- PubMed search: vilon clinical trial humansLive PubMed query confirming the absence of indexed human trials
Cite this page
PepCue. “Vilon: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/vilon.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.